AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7930477 — intervention group
Group type: COMPARATOR
Intervention: Leg glucose uptake
Number of subjects: 13
Study 3063718 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 19
Study 3063718 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.30 mg/kg
Number of subjects: 19
Study 3063718 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.60 mg/kg
Number of subjects: 19
Study 31212100 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Care (SusC)
Number of subjects: 353
Study 31212100 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 353
Study 27936811 — intervention group
Group type: EXPERIMENTAL
Intervention: TeenDrivingPlan (TDP)
Number of subjects: 295
Study 27936811 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 295
Study 27936811 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice diversity
Number of subjects: 295
Study 27936811 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents' perceptions of adolescents' skill in comparison to peers
Number of subjects: 295
Study 26222750 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole Vaginal Gel 1.3%
Number of subjects: 651
Study 26222750 — intervention group
Group type: COMPARATOR
Intervention: Vehicle Gel
Number of subjects: 651
Study 24397194 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin therapy for 24 weeks (genotypes 2 and 3) or 48 weeks (genotypes 1 and 4)
Number of subjects: 52
Study 24397194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prisoners with virus genotype 1
Number of subjects: 52
Study 21512184 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 973
Study 21512184 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 973
Study 19115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg)
Number of subjects: 21
Study 19115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine (LMV, 300 mg)
Number of subjects: 21
Study 19115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (TDF/LMV)
Number of subjects: 21
Study 19115219 — intervention group
Group type: COMPARATOR
Intervention: HBeAg-positive individuals
Number of subjects: 21
Study 16681329 — intervention group
Group type: EXPERIMENTAL
Intervention: Two invitation letters
Number of subjects: 3144
Study 16681329 — intervention group
Group type: EXPERIMENTAL
Intervention: One invitation letter plus a follow-up telephone call
Number of subjects: 3144
Study 16681329 — intervention group
Group type: COMPARATOR
Intervention: One invitation letter (standard practice)
Number of subjects: 3144
Study 16681329 — intervention group
Group type: EXPERIMENTAL
Intervention: One invitation letter plus a phone call (for women where a phone number was located)
Number of subjects: 3144
Study 14648129 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Rest Protocol (SRP) - 3 sets of 50 repetitions with 2 min total rest
Number of subjects: 8
Study 14648129 — intervention group
Group type: COMPARATOR
Intervention: Long Rest Protocol (LRP) - 15 sets of 10 repetitions with 14 min total rest
Number of subjects: 8
Study 14648129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols (SRP and LRP)
Number of subjects: 8
Study 11763011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine 16 mg/day
Number of subjects: 30
Study 11763011 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 80 mg/day
Number of subjects: 30
Study 9395750 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent pharmacological interventions for portal hypertension
Number of subjects: 0
Study 9395750 — intervention group
Group type: EXPERIMENTAL
Intervention: Current clinical research
Number of subjects: 0
Study 8131380 — intervention group
Group type: COMPARATOR
Intervention: DSM-III
Number of subjects: 454
Study 8131380 — intervention group
Group type: EXPERIMENTAL
Intervention: DSM-III-R
Number of subjects: 454
Study 30885882 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable gluten sensor device (Nima)
Number of subjects: 0
Study 30885882 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29082462 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) with 940 nm diode laser, 7 sessions over 2 weeks
Number of subjects: 19
Study 29082462 — intervention group
Group type: COMPARATOR
Intervention: Control group (laser hand piece in 'off' mode)
Number of subjects: 19
Study 26428200 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin adhesive (SA)
Number of subjects: 77
Study 26428200 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous suture (TS)
Number of subjects: 77
Study 26428200 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA and TS
Number of subjects: 77
Study 24567366 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus selumetinib
Number of subjects: 83
Study 24567366 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus placebo
Number of subjects: 83
Study 22067809 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (single-sided gel delivery)
Number of subjects: 36
Study 22067809 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (double-sided gel delivery)
Number of subjects: 36
Study 22067809 — intervention group
Group type: COMPARATOR
Intervention: Gel applicator
Number of subjects: 36
Study 22067809 — intervention group
Group type: EXPERIMENTAL
Intervention: SILCS diaphragm (single-sided and double-sided gel delivery)
Number of subjects: 36
Study 20673054 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% benzalkonium chloride (BAC) solution, applied three times daily for 12 weeks
Number of subjects: 20
Study 20673054 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution, applied three times daily for 12 weeks
Number of subjects: 20
Study 19128624 — intervention group
Group type: EXPERIMENTAL
Intervention: IT dexamethasone injection
Number of subjects: 52
Study 19128624 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 52
Study 16394299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentavalent human-bovine (WC3 strain) reassortant rotavirus vaccine
Number of subjects: 68038
Study 16394299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68038
Study 12828801 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil 1 (VOO1)
Number of subjects: 31
Study 12828801 — intervention group
Group type: COMPARATOR
Intervention: Virgin Olive Oil 2 (VOO2)
Number of subjects: 31
Study 10390266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone therapy (6 doses at 12-hour intervals starting at 24 to 48 hours of life)
Number of subjects: 241
Study 10390266 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 241
Study 8695241 — intervention group
Group type: COMPARATOR
Intervention: G-CSF
Number of subjects: 54
Study 8695241 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF + TS
Number of subjects: 54
Study 1738412 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.01 micrograms/min/kg
Number of subjects: 6
Study 1738412 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.05 micrograms/min/kg
Number of subjects: 6
Study 1738412 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 infusion at 0.1 micrograms/min/kg
Number of subjects: 6
Study 1738412 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving vehicle infusion without PGE1
Number of subjects: 6
Study 6828682 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon (0.05 mg/kg)
Number of subjects: 30
Study 6828682 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.05 mg/kg)
Number of subjects: 30
Study 6828682 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon and Placebo
Number of subjects: 30
Study 31607313 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose DAC 10 mg/(m2·d)×7 d
Number of subjects: 51
Study 31607313 — intervention group
Group type: COMPARATOR
Intervention: Normal dose DAC 20 mg/(m2·d) ×5 d
Number of subjects: 51
Study 31607313 — intervention group
Group type: COMPARATOR
Intervention: Low dose DAC+CAG (DAC 10 mg/(m2·d) d 1‐5, cytarabine 10 mg/(m2·d) q12h d 1‐7, aclaromycin 10 mg/d d 1‐4, G‐CSF 200 μg/(m2·d), d 1‐7)
Number of subjects: 51
Study 29925916 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 42
Study 29925916 — intervention group
Group type: COMPARATOR
Intervention: sham-TEA
Number of subjects: 42
Study 27365226 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and physiotherapy (six 30-minute sessions over 4 months)
Number of subjects: 29
Study 27365226 — intervention group
Group type: COMPARATOR
Intervention: Advice (one-off session with advice booklets)
Number of subjects: 29
Study 27365226 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice and physiotherapy
Number of subjects: 29
Study 27365226 — intervention group
Group type: COMPARATOR
Intervention: Advice
Number of subjects: 29
Study 23495677 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/day phosphatidylserine (PS) for 2 months
Number of subjects: 36
Study 23495677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 22081981 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-rich bread (2.2 mg iron per 50 g slice) consumed at an average of 2.3 slices per day for 6 weeks
Number of subjects: 34
Study 22081981 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 34
Study 20110052 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles plus ketoconazole 400 mg on days 6, 7, 8, and 9 of cycle 1
Number of subjects: 21
Study 20110052 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib 1.0 mg/m² IV on days 1, 4, 8, and 11 of two 21-day cycles without ketoconazole
Number of subjects: 21
Study 17488902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 50 mg/kg
Number of subjects: 497
Study 17488902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 25 mg/kg
Number of subjects: 497
Study 17488902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine 15 mg/kg
Number of subjects: 497
Study 17488902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (general)
Number of subjects: 497
Study 15174219 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 50
Study 15174219 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 11744026 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cross‐clamp fibrillation (control)
Number of subjects: 30
Study 11744026 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological preconditioning (GR79236X)
Number of subjects: 30
Study 11744026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning
Number of subjects: 30
Study 9626150 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mU/min insulin
Number of subjects: 17
Study 9626150 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mU/min insulin
Number of subjects: 17
Study 9626150 — intervention group
Group type: COMPARATOR
Intervention: vehicle (placebo)
Number of subjects: 17
Study 7812199 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-Cis retinoic acid (13-CRA)
Number of subjects: 0
Study 7812199 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 0
Study 7812199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2508260 — intervention group
Group type: EXPERIMENTAL
Intervention: dDAVP followed by standard heparin
Number of subjects: 8
Study 2508260 — intervention group
Group type: COMPARATOR
Intervention: dDAVP followed by saline
Number of subjects: 8
Study 2508260 — intervention group
Group type: EXPERIMENTAL
Intervention: standard heparin
Number of subjects: 8
Study 808359 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable isosorbide dinitrate (CHIS), 10 mg
Number of subjects: 8
Study 808359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin (NTG), 0.6 mg
Number of subjects: 8
Study 808359 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P), two chewable tablets
Number of subjects: 8
Study 30005170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother's Milk® herbal tea (test)
Number of subjects: 60
Study 30005170 — intervention group
Group type: COMPARATOR
Intervention: Lemon verbena leaf (placebo)
Number of subjects: 60
Study 28093356 — intervention group
Group type: EXPERIMENTAL
Intervention: PCT+LLLT
Number of subjects: 15
Study 28093356 — intervention group
Group type: COMPARATOR
Intervention: LLLT alone
Number of subjects: 15
Study 25438099 — intervention group
Group type: EXPERIMENTAL
Intervention: Conical implants with wide pitch (group 1)
Number of subjects: 20
Study 24032271 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg r-hCG
Number of subjects: 72
Study 24032271 — intervention group
Group type: COMPARATOR
Intervention: 500 microg r-hCG
Number of subjects: 72
Study 21807325 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and carvedilol
Number of subjects: 90
Study 21807325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 19424093 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% DHEA (Prasterone)
Number of subjects: 216
Study 19424093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 16396728 — intervention group
Group type: EXPERIMENTAL
Intervention: High-velocity thrust manipulation
Number of subjects: 70
Study 12764959 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating-pressure mattresses
Number of subjects: 0
Study 12764959 — intervention group
Group type: COMPARATOR
Intervention: Overlays
Number of subjects: 0
Study 10889124 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of orbofiban twice daily (50/50 group)
Number of subjects: 10288
Study 10889124 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of orbofiban twice daily for 30 days followed by 30 mg of orbofiban twice daily (50/30 group)
Number of subjects: 10288
Study 10889124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10288
Study 10889124 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who underwent percutaneous coronary intervention
Number of subjects: 10288
Study 8629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with a distracting task (78-minute protocol with 6-minute baselines and 12-minute testing conditions)
Number of subjects: 20
Study 8629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Masturbation after removal of the distracting task
Number of subjects: 20
Study 8629915 — intervention group
Group type: COMPARATOR
Intervention: Performance of a distracting task with manual genital stimulation
Number of subjects: 20
Study 8629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of the distracting task
Number of subjects: 20
Study 8629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genital responses in able-bodied women
Number of subjects: 20
Study 8629915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall genital responses in women with SCI
Number of subjects: 20
Study 1568517 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzathine penicillin G (1,200,000 IU given intramuscularly)
Number of subjects: 20
Study 1568517 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V (250 mg given orally twice daily)
Number of subjects: 20
Study 1568517 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin stearate (250 mg given orally twice daily)
Number of subjects: 20
Study 1568517 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin (150 mg given orally once daily)
Number of subjects: 20
Study 3839407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 27
Study 3839407 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 27
Study 3839407 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 27
Study 3839407 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 31629439 — intervention group
Group type: EXPERIMENTAL
Intervention: PK Button
Number of subjects: 78
Study 31629439 — intervention group
Group type: COMPARATOR
Intervention: Monopolar loop
Number of subjects: 78
Study 31629439 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 78
Study 29167892 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumor location
Number of subjects: 1869
Study 29167892 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumors with RAS mutations
Number of subjects: 1869
Study 29167892 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-sided tumors with RAS and BRAF double wild type
Number of subjects: 1869
Study 29167892 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab
Number of subjects: 1869
Study 28963937 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% of maximal voluntary force (MVC) for 30min
Number of subjects: 18
Study 28963937 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% of maximal voluntary force (MVC) until task-failure
Number of subjects: 18
Study 28963937 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG activity during contractions
Number of subjects: 18
Study 28963937 — intervention group
Group type: EXPERIMENTAL
Intervention: Post hoc matched strength (n=10)
Number of subjects: 18
Study 25679343 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic Therapeutic Taping (ETT)
Number of subjects: 16
Study 25679343 — intervention group
Group type: COMPARATOR
Intervention: Rigid Therapeutic Taping (RTT)
Number of subjects: 16
Study 25679343 — intervention group
Group type: COMPARATOR
Intervention: No Tape
Number of subjects: 16
Study 23195665 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 seconds papillary balloon dilation (G60, n = 60)
Number of subjects: 124
Study 23195665 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 seconds papillary balloon dilation (G30, n = 64)
Number of subjects: 124
Study 21075025 — intervention group
Group type: EXPERIMENTAL
Intervention: CRPS-IgG injected groups
Number of subjects: 12
Study 21075025 — intervention group
Group type: COMPARATOR
Intervention: Control-IgG injected groups
Number of subjects: 12
Study 18003795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HF)
Number of subjects: 10
Study 18003795 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 10
Study 18003795 — intervention group
Group type: EXPERIMENTAL
Intervention: CCK-8 infusion (2 ng.kg(‐1).min(‐1))
Number of subjects: 10
Study 16556903 — intervention group
Group type: EXPERIMENTAL
Intervention: Local blockade of nitric oxide and prostaglandins using nitro‐L‐arginine methyl ester and indomethacin during one‐legged dynamic knee‐extension exercise
Number of subjects: 7
Study 16556903 — intervention group
Group type: EXPERIMENTAL
Intervention: Local blockade of nitric oxide and prostaglandins
Number of subjects: 7
Study 14980088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine (TM)
Number of subjects: 62
Study 10932513 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin 0.3%
Number of subjects: 41
Study 10932513 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin (50 mg/ml) and fortified gentamicin (14 mg/ml)
Number of subjects: 41
Study 9298049 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aminocaproic acid
Number of subjects: 64
Study 9298049 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic aminocaproic acid
Number of subjects: 64
Study 9298049 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 8393888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 14
Study 8393888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) with 1 microgram/kg ovine CRH
Number of subjects: 14
Study 8393888 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg) with 0.25 microgram ACTH-(1-24)
Number of subjects: 14
Study 2437713 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinagel
Number of subjects: 148
Study 2437713 — intervention group
Group type: COMPARATOR
Intervention: Debrisan Paste
Number of subjects: 148
Study 31806071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 282
Study 31806071 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 282
Study 29304862 — intervention group
Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile produce market
Number of subjects: 142
Study 29304862 — intervention group
Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) customers
Number of subjects: 142
Study 29304862 — intervention group
Group type: COMPARATOR
Intervention: Non-customers (control)
Number of subjects: 142
Study 29304862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention participants
Number of subjects: 142
Study 27580566 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin treatment
Number of subjects: 65
Study 24002623 — intervention group
Group type: EXPERIMENTAL
Intervention: CARVE-OUT (outsourced approach with telephone-based diabetes educator)
Number of subjects: 486
Study 24002623 — intervention group
Group type: COMPARATOR
Intervention: CARVE-IN (clinic-based approach with clinic nurse)
Number of subjects: 486
Study 23369169 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical management
Number of subjects: 36
Study 23369169 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 36
Study 21690207 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium ranelate (SrRan)
Number of subjects: 34
Study 19086331 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral lansoprazole (LODT) 30 mg mixed in 10 mL of water via a nasal gastric tube
Number of subjects: 19
Study 19086331 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lansoprazole (IV-L) 30 mg over 30 min
Number of subjects: 19
Study 17073356 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 12
Study 17073356 — intervention group
Group type: COMPARATOR
Intervention: Delayed loading implants (control)
Number of subjects: 12
Study 14513918 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg)
Number of subjects: 24